In addition to demonstrating improvements in cardiometabolic health without signs of liver damage, animals treated with GLP-1-MK-801 exhibited relatively mild common side effects associated with GLP-1 agonists (nausea) and NMDA receptor antagonists (hyperthermia and hyperactivity)
Fifty-eight percent (58%) of the population were male
Some mild nausea may occur, particularly in the first week of each dose increase
The medullary thyroid carcinoma warning All GLP-1 receptor agonists carry a black-box warning, the most serious warning the FDA issues, regarding thyroid C-cell tumors
While regulatory bodies and pharmaceutical companies are discussing potential solutions to the drug shortages, societies such as the American Diabetes Association are providing guidelines to assist with alternative treatment options for patients with type 2 diabetes mellitus as well as guidelines to assist with dosage changes to be made while GLP-1 therapies are low in stock
Women seem to be more willing to tolerate and work through the significant side effects of the drugs, which can include regular nausea, vomiting and constipation
